TFX
BuyHot AirFLAGTeleflex Incorporated · Healthcare · United States · $5.9B · Avg Vol: $83M/d
Hot Air: Rising on momentum alone: weak business, rich price.
Insufficient evidence for a screen-pass. Teleflex Incorporated: fails the quant gate on quality, value (Q45/V45/M76; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT TELEFLEX INCORPORATED
Read
Teleflex Incorporated is a global provider of specialized medical technologies aimed at improving patient health, focusing on product areas such as vascular access, anesthesia, surgical, urology, and interventional cardiology. Its competitive moat is formed by proprietary technologies, robust clinical evidence supporting product efficacy, and established relationships with healthcare providers worldwide. Teleflex is a key innovator in acute care and surgical medical devices.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8B | 1.7B | 1.7B | 2.0B | -10.6% | 2.3B | 2.3B | 2.4B | 9.2% |
| EPS | 7.74 | 7.58 | 1.49 | -20.30 | -56.1% | -0.53 | — | — | — |
| Shares | 46.9M | 47.0M | 46.3M | 44.2M | -5.8% | 42.4M | — | — | — |
| Debt | 1.8B | 1.9B | 1.7B | 2.7B | 14.2% | 2.9B | — | — | — |
| Equity | 4.0B | 4.4B | 4.3B | 3.1B | -8.1% | — | — | — | — |
| Op CF | 342.1M | 510.6M | 635.7M | 340.7M | -0.1% | 403.2M | — | — | — |
| Inv CF | -257.9M | -621.2M | -99.4M | -849.2M | — | — | — | — | — |
| Fin CF | -217.5M | 38.5M | -421.9M | 611.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TFX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TFX | Teleflex Incorporated(you) | $5.9B | 66 | Buy |
| ICUI | ICU Medical, Inc. | $4.4B | 63 | Hold |
| AVTR | Avantor, Inc. | $9.9B | 70 | Buy |
| ATR | AptarGroup, Inc. | $8.5B | 74 | Buy |
| MMSI | Merit Medical Systems, Inc. | $5.4B | 82 | Strong Buy |
| COO | The Cooper Companies, Inc. | $13.9B | 64 | Hold |
| ATRC | AtriCure, Inc. | $2.5B | 64 | Hold |
| BAX | Baxter International Inc. | $13.5B | 73 | Buy |
| NVST | Envista Holdings Corporation | $4.4B | 85 | Strong Buy |
| RGEN | Repligen Corporation | $9.9B | 50 | Hold |
Peer medians: ROE -31.0% · P/E 25.1x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.